Beiley Biofund Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Revenue	0.26	-	-
Other Revenue	1,227	140.54	139.5
Revenue	1,227	140.54	139.5
Revenue Growth (YoY)	773.27%	0.74%	-
Gross Profit	1,227	140.54	139.5
Selling, General & Admin	72.32	49.82	57.4
Amortization of Goodwill & Intangibles	-	0	-
Operating Expenses	72.32	51.67	57.58
Operating Income	1,155	88.87	81.92
Interest Expense	-0.01	-0.04	-0.01
Interest & Investment Income	16.79	15.21	4.06
Currency Exchange Gain (Loss)	0.59	1.44	-
Other Non Operating Income (Expenses)	0.01	0.03	1.5
EBT Excluding Unusual Items	1,172	105.51	87.47
Gain (Loss) on Sale of Investments	0.36	6.12	1.15
Pretax Income	1,173	111.63	88.63
Income Tax Expense	47.09	15.12	0.01
Net Income	1,126	96.51	88.62
Net Income to Common	1,126	96.51	88.62
Net Income Growth	1066.28%	8.91%	-
Shares Outstanding (Basic)	205	205	90
Shares Outstanding (Diluted)	205	205	90
Shares Change (YoY)	0.04%	127.18%	-
EPS (Basic)	5.48	0.47	0.98
EPS (Diluted)	5.48	0.47	0.98
EPS Growth	1065.96%	-52.04%	-
Free Cash Flow	-35.4	216.57	-569.02
Free Cash Flow Per Share	-0.17	1.05	-6.30
Dividend Per Share	1.400	0.150	-
Dividend Growth	833.33%	-	-
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	94.11%	63.24%	58.73%
Profit Margin	91.72%	68.67%	63.52%
Free Cash Flow Margin	-2.89%	154.10%	-407.90%
EBITDA	1,156	89.68	81.93
EBITDA Margin	94.23%	63.81%	58.73%
D&A For EBITDA	1.49	0.81	0.01
EBIT	1,155	88.87	81.92
EBIT Margin	94.11%	63.24%	58.73%
Effective Tax Rate	4.02%	13.55%	0.01%
Revenue as Reported	1,227	140.54	-